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Enterovirus antibody titers after IVIG replacement in
agammaglobulinemic children
Patients who su¡er from hypo- or agammaglobulinemia are
at risk of severe chronic meningo-encephalitis caused by an
enterovirus [1]. Intravenous immunoglobulins (IVIG) can be
o¡ered prophylactically [2^4], but once chronic meningo-
encephalitis is established, IVIG treatment is seldom e¡ective,
even when given intrathecally. Therefore the emphasis is on
prophylaxis, although there are no data in the literature that
indicate how this can be achieved optimally. In a previous
study we showed that antibody levels against di¡erent entero-
virus serotypes vary within a single IVIG batch up to a 100-
fold, and up to 10-fold di¡erences were found between
batches.The highest titer observed, was 1: 10 000 and the low-
est titer was 1: 40 [5]. It is not knownwhether or not such low
titers might reduce therapeutic e¤cacy, nor does it give any
indication of the titers that might be attained in a recipient. In
order to understand better how prophylaxis will be optimally
achieved, we investigated peak and through levels of entero-
virus-speci¢c antibody in serum of IVIG recipients who suf-
fered from agammaglobulinemia. Three patients were
analyzed. Patient A su¡ered from immunode¢ciency, cen-
tromeral instability and facial abnormality (ICF) syndrome
and has been described in detail [6]. Patients B and C were
diagnosed as su¡ering from X-linked agammaglobulinemia
(XLA). Patient C was recently diagnosed. From this patient,
pretreatment serum samples were available, as well as samples
collected after the ¢rst dose (0.5 g/kg), and after a second dose
of 0.3 g/kg IVIG, given 12 days after the ¢rst dose. Patients A
and B had been on maintenance treatment for years.The IVIG
was administered in 3 h. Maintenance therapy was given at a
dose of 0.5 g/kg (patient A) and 0.6 g/kg (patient B), given
once in 3weeks. Blood was drawn shortly before administra-
tion of IVIG and 30min after infusion of IVIG was ¢nished.
The serum was collected and stored at ÿ80 C for use in a
virus neutralization test (VNT). All serum samples from an
individual were tested on the same day.The IVIG preparation
used throughout the study was from a single lot: CLB-
961004 -H62A obtained from the Central Laboratory of the
Netherlands Red Cross Blood transfusion Service (CLB);
Amsterdam, the Netherlands. The Ig concentration was 6 g/
100mL.
The following prototype virus strains were used: Coxsackie
B virus (CVB) types 3 (TvDee), 4 (Tilo) and 5 (Dekking) and
ECHO virus (EV) types 9 (Meyer), 19 (Burke), and 29 ( JV-
10). Preparation of viral stocks, titration and VNTwere per-
formed as previously described [5].
The antibody titers (reciprocal of dilution) in the IVIG pre-
paration were, respectively: CVB3, 810; CVB4, 3230; CVB5,
480; EV9, 340; EV19, 140; EV29, 30.Table 1 shows the trough
and peak levels obtained for the three patients. Antibodies pre-
sent in the ¢rst trough sample obtained from patients A and B
were derived from another IVIG lot that was no longer avail-
able for antibody testing.The ¢rst serum frompatient C repre-
sented a pretreatment sample and was completely negative for
enterovirus antibody. In general, peak levels were obtained
that were twice as high as the trough levels and a tenth of the
levels in the IVIG preparation itself. The antibody levels
roughly corresponded with the IgG concentration in serum,
which was also a tenth of that in the IVIG preparation. For
EV29, with a titer of 1: 30 in the IVIG, serum antibody levels
remained below the detection limit of 1: 4 in most of the sam-
ples.
In a previous study we have shown that antibody titers in
IVIG preparations do not re£ect the incidence of infections by
the particular serotype during the period that plasmawas col-
lected from donors. Low titers were found for some viruses
that circulate frequently and are a real risk for exposure [5].
Therefore, we checked the antibody titers achieved in serum
of patients on IVIG maintenance treatment. The viral sero-
types used for the study were selected on antibody titers in the
IVIG lot being high, intermediate and low. Four of the six ser-
otypes have been reported to cause chronic enteroviral
menigo-encephalitis in agammaglobulinemic patients [2]. As
shown, peak levels in serumwere 5- to 10-fold lower than in
the IVIG preparation itself.Trough levels were about half these
values. Antibody titers were measurable for ¢ve out of the six
viruses. For EV29, whichwas selected because of a low titer in
IVIG (1: 30), serum levels remained under the detection limit
of 1: 4 and it is questionable whether such a low titer is e¡ec-
tive in vivo. Ultimate proof of e¤cacy can only be obtained by
clinical evaluation. Such evaluations have shown a clear reduc-
tion in chronic enteroviral infections after introduction of
IVIG [7]. However, and in spite of such treatment, chronic
enteroviral meningoencephalitis does still occur, even under a
high-dose regime with serum IgG levels above 6 g/L [8,9].
Such failures might be due to intratypic variations between
virus isolates, which indicates that some strains are poorly neu-
tralized by pre-existing type-speci¢c antibody [5]. Further-
more, it is uncertain whether IVIG will provide protection at
mucosal sites which are the portal of entry for enteroviruses.
Similarly, IVIG is poorly e¡ective within the central nervous
system because of the blood^brain barrier, which limits pas-
sage of IgG. Presumably the protective role of IVIG is to pre-
vent viremia and a subsequent migration of the virus to the
central nervous system and to other vulnerable systems such as
heart and skeletal muscle.
Antibody levels have previously been determined in neo-
nates treated with IVIG for neonatal enterovirus infection
[10]. It is di¤cult to compare our results with those of that
study because maternal antibody was present in some of the
neonates before infusion. Furthermore, the study did not
show changes in antibody levels for individual neonates. In
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another study antibodies against various other micro-organ-
isms were determined in the serum of agammaglobulinemic
patients but information on antibody levels in the IVIG pre-
paration was missing [11].We are not aware of any other study
on antibody levels against enteroviruses in vivo. It is concluded
that IVIG can contain low antibody titers (<1: 50) [5,11].
Application of such IVIG lots for replacement therapy may
result in undetectable antibody levels in serum and presum-
ably in a low protective e¤cacy. From these observations it can
be argued that a high dose of IVIG of 200mg/kg per week
should be preferred to the usual dose of 100mg/kg per week.
A clinical evaluation of these two dosages is presently under
investigation [12].
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Table 1 Antibody titers in serum of IVIG recipients
Serotype
Recipient A (ICF)
Trough 0 Peak Trough 1
CBV3 48 95 34
CBV4 100 269 105
CBV5 23 48 16
EV9 20 50 17
EV19 8 14 9
EV29 <4 <4 <4
IgG 4.1 g/L 8.2 g/L 3.3 g/L
Recipient B (XLA)
Trough 0 Peak Trough 1
CBV3 93 186 95
CBV4 158 380 132
CBV5 42 93 42
EV9 45 117 63
EV19 8 40 12
EV29 <4 5 <4
IgG 7.0 g/L 16.2 g/L 7.9 g/L
Recipient C (newly diagnosed XLA)
Untreated Peak 1 Trough 1 Peak 2 Trough 2
CBV3 <4 63 29 93 47
CBV4 <4 195 43 166 72
CBV5 <4 55 15 74 24
EV9 <4 64 16 55 23
EV19 <4 22 6 27 6
EV29 <4 <4 <4 < 4 <4
IgG 0.2 g/L 6.4 g/L 3.1 g/L 7.0 g/L 3.3 g/L
CBV, Coxsackie B virus; EV, ECHOvirus.
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